Form 4: Niagen Bioscience Director Hamed Shahbazi Granted 20,000 Stock Options

Hamed Shahbazi, a Director at Niagen Bioscience, Inc., was granted 20,000 stock options with an exercise price of $14.13, which will fully vest on June 24, 2026.

Summary

• Hamed Shahbazi, a Director of Niagen Bioscience, Inc. (NAGE), was granted 20,000 stock options.
• The transaction date for this grant was June 24, 2025.
• Each stock option has an exercise price of $14.13.
• The options were acquired at a price of $0 per option.
• These options grant the right to buy 20,000 shares of Niagen Bioscience Common Stock.
• The options will vest 100% on June 24, 2026.
• The expiration date for these stock options is June 23, 2035.
• Following this transaction, Hamed Shahbazi directly beneficially owns 20,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, as it aligns the director's financial interests with the long-term performance of the company and shareholder value. It indicates continued commitment and confidence from an insider.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options' value increases with the company's stock price.
• An insider acquiring equity, even through a grant, can signal confidence in the company's future prospects.

Future Outlook

The stock options granted to Director Hamed Shahbazi are set to vest fully on June 24, 2026, indicating a future milestone for the equity compensation.

Industry Context

This Form 4 filing is a standard disclosure of an insider equity transaction, common across all publicly traded companies as part of executive and director compensation packages. It reflects a routine aspect of corporate governance and incentive alignment.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns the director's incentives with shareholder value creation, potentially encouraging long-term performance focus.

Next Steps

• The stock options will vest 100% on June 24, 2026, at which point the director will be able to exercise them.

Key Dates

Keywords

Niagen Bioscience, NAGE, Hamed Shahbazi, stock options, insider transaction, SEC Form 4, director compensation, equity grant